|Category:||Emerging Biotech Company|
|Date:||April 24, 2023|
|Speaker:||Mohaned Shilaih, Co-founder|
At FimmCyte our vision is to create the first disease modifying treatment for endometriosis. Every tenth woman has endometriosis, but besides pain management and surgery there are no alternatives. We have developed a novel antibody based, non-hormonal therapy (FMC2), which has proven to be highly effective in patient and allograft in-vivo models, as well as ex-vivo models. We are excited to translate our work from the lab to the clinic with strategic partners and investors.